NTRA Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -13.34% compared to Natera's net margin of 5.4%. Natera's return on equity of -19.19% beat Delcath Systems's return on equity of -40.28%.

Natera has a consensus price target of $192.78, signalling upside risk potential of 14.78%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 77.18%. Given that Delcath Systems has higher upside potential than Natera, analysts believe Delcath Systems is more attractive than Natera.

Natera has a beta of 1.741, which suggesting that the stock is 74.102% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.238%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Natera quarterly revenues are $501.8M, which are larger than Delcath Systems quarterly revenues of $19.8M. Natera's net income of -$66.9M is lower than Delcath Systems's net income of $1.1M. Notably, Natera's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 11.76x versus 8.34x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -13.34% compared to Natera's net margin of -14.32%. Natera's return on equity of -19.19% beat Exact Sciences's return on equity of -35.57%.

Natera has a consensus price target of $192.78, signalling upside risk potential of 14.78%. On the other hand Exact Sciences has an analysts' consensus of $68.46 which suggests that it could grow by 27.6%. Given that Exact Sciences has higher upside potential than Natera, analysts believe Exact Sciences is more attractive than Natera.

Natera has a beta of 1.741, which suggesting that the stock is 74.102% more volatile than S&P 500. In comparison Exact Sciences has a beta of 0.977, suggesting its less volatile than the S&P 500 by 2.282%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Natera quarterly revenues are $501.8M, which are smaller than Exact Sciences quarterly revenues of $706.8M. Natera's net income of -$66.9M is higher than Exact Sciences's net income of -$101.2M. Notably, Natera's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 11.76x versus 3.52x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of -13.34% compared to Natera's net margin of -46.77%. Natera's return on equity of -19.19% beat Guardant Health's return on equity of -8518.58%.

Natera has a consensus price target of $192.78, signalling upside risk potential of 14.78%. On the other hand Guardant Health has an analysts' consensus of $59.66 which suggests that it could grow by 17.31%. Given that Guardant Health has higher upside potential than Natera, analysts believe Guardant Health is more attractive than Natera.

Natera has a beta of 1.741, which suggesting that the stock is 74.102% more volatile than S&P 500. In comparison Guardant Health has a beta of 1.373, suggesting its more volatile than the S&P 500 by 37.333%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Natera pays -- of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend.

Natera quarterly revenues are $501.8M, which are larger than Guardant Health quarterly revenues of $203.5M. Natera's net income of -$66.9M is higher than Guardant Health's net income of -$95.2M. Notably, Natera's price-to-earnings ratio is -- while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 11.76x versus 8.10x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of -13.34% compared to Natera's net margin of 6.36%. Natera's return on equity of -19.19% beat Labcorp Holdings's return on equity of 9.01%.

Natera has a consensus price target of $192.78, signalling upside risk potential of 14.78%. On the other hand Labcorp Holdings has an analysts' consensus of $277.23 which suggests that it could grow by 6.39%. Given that Natera has higher upside potential than Labcorp Holdings, analysts believe Natera is more attractive than Labcorp Holdings.

Natera has a beta of 1.741, which suggesting that the stock is 74.102% more volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.812, suggesting its less volatile than the S&P 500 by 18.757%.

Natera has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings offers a yield of 1.11% to investors and pays a quarterly dividend of $0.72 per share. Natera pays -- of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Labcorp Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Natera quarterly revenues are $501.8M, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Natera's net income of -$66.9M is lower than Labcorp Holdings's net income of $212.8M. Notably, Natera's price-to-earnings ratio is -- while Labcorp Holdings's PE ratio is 30.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Natera is 11.76x versus 1.67x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.